Genix Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Revenue	-	-	0	0.01	-	-
Revenue Growth (YoY)	-	-	-67.19%	-	-	-
Cost of Revenue	-	-	0	0.01	-	-
Gross Profit	-	-	0	0	-	-
Selling, General & Admin	0.13	0.16	0.25	0.89	1.03	1.66
Depreciation & Amortization Expenses	0	0	0	0.55	0.56	0.54
Other Operating Expenses	0	0.01	0	0	0	0
Total Operating Expenses	0.13	0.16	0.25	1.44	1.6	2.2
Operating Income	-0.13	-0.16	-0.25	-0.88	-1.03	-1.66
Interest Income	0	0	0	0	0	0
Interest Expense	-0.17	-0.17	-0.12	-0.05	-0.01	-
Other Non-Operating Income (Expense)	0.03	-0.01	0.29	-3.46	-0.03	0
Total Non-Operating Income (Expense)	-0.15	-0.18	0.17	-3.51	-0.04	0.01
Pretax Income	-0.13	-0.16	-0.25	-0.88	-1.03	-1.66
Net Income	-0.13	-0.16	-0.25	-0.88	-1.03	-1.66
Net Income to Common	-0.13	-0.16	-0.25	-0.88	-1.03	-1.66
Shares Outstanding (Basic)	60	60	59	59	59	59
Shares Outstanding (Diluted)	60	60	59	59	59	59
Shares Change (YoY)	1.38%	0.54%	-	-	-	18.55%
EPS (Basic)	-0.01	-0.01	-	-0.07	-0.02	-0.03
EPS (Diluted)	-0.01	-0.01	-	-0.07	-0.02	-0.03
Free Cash Flow	-0.09	-0.12	-0.19	-0.22	-0.22	-0.43
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.00	-0.01
Gross Margin	-	-	32.02%	26.43%	-	-
Operating Margin	-	-	-6061.66%	-7158.82%	-	-
Profit Margin	-	-	-6061.66%	-7158.82%	-	-
FCF Margin	-	-	-4624.54%	-1787.27%	-	-
EBITDA	-0.13	-0.16	-0.24	-0.34	-0.47	-1.12
EBITDA Margin	-	-	-6033.72%	-2725.19%	-	-
EBIT	-0.13	-0.16	-0.25	-0.88	-1.03	-1.66
EBIT Margin	-	-	-6061.66%	-7158.82%	-	-